101 related articles for article (PubMed ID: 26739927)
21. Could bystander killing contribute significantly to the antitumor activity of brentuximab vedotin given with standard first-line chemotherapy for Hodgkin lymphoma?
Brown MP; Staudacher AH
Immunotherapy; 2014; 6(4):371-5. PubMed ID: 24815777
[TBL] [Abstract][Full Text] [Related]
22. Brentuximab vedotin: a new age in the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma.
Minich SS
Ann Pharmacother; 2012 Mar; 46(3):377-83. PubMed ID: 22395252
[TBL] [Abstract][Full Text] [Related]
23. Alternative salvage regimens for relapsed/refractory classical Hodgkin's lymphoma.
Magyari F; Barna S; Husi K; Simon Z; Miltényi Z; Váróczy L; Udvardy M; Illés Á
Hematology; 2016 Aug; 21(7):404-10. PubMed ID: 26907830
[TBL] [Abstract][Full Text] [Related]
24. Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin.
Zinzani PL; Derenzini E; Pellegrini C; Celli M; Broccoli A; Argnani L
Br J Haematol; 2013 Dec; 163(5):681-3. PubMed ID: 24032977
[No Abstract] [Full Text] [Related]
25. Successful treatment of systemic EBV positive T-cell lymphoma of childhood using the SMILE regimen.
Yoshida M; Osumi T; Imadome KI; Tomizawa D; Kato M; Miyazawa N; Ito R; Nakazawa A; Matsumoto K
Pediatr Hematol Oncol; 2018 Mar; 35(2):121-124. PubMed ID: 29648917
[No Abstract] [Full Text] [Related]
26. Successful rapid desensitization to the antibody-drug conjugate brentuximab vedotin in a patient with refractory Hodgkin lymphoma.
Fizesan M; Boin C; Aujoulat O; Newinger G; Ghergus D; Watier H; Lustig H; Ojeda-Uribe M
J Oncol Pharm Pract; 2016 Feb; 22(1):188-92. PubMed ID: 25586990
[No Abstract] [Full Text] [Related]
27. Unique evolution of angioimmunoblastic T cell lymphoma to Epstein-Barr virus-positive plasma cell myeloma.
Chan TSY; Ip AHW; Au-Yeung R; Pang AWK; Kwong YL
Ann Hematol; 2020 Dec; 99(12):2949-2952. PubMed ID: 32514627
[No Abstract] [Full Text] [Related]
28. In brief: Brentuximab vedotin (Adcetris) for classical hodgkin's lymphoma.
Med Lett Drugs Ther; 2018 Nov; 60(1559):e185. PubMed ID: 30681659
[No Abstract] [Full Text] [Related]
29. Real-time ultrasound elastography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.
Squillaci E; Antonicoli M; Manenti G; Bolacchi F
Eur Rev Med Pharmacol Sci; 2016 Apr; 20(8):1628-35. PubMed ID: 27160139
[TBL] [Abstract][Full Text] [Related]
30. Brentuximab vedotin and anti-PD1 treatment optimize survival in chemo-refractory Hodgkin lymphoma patients: Real-world data.
Sakellari I; Gavriilaki E; Iskas M; Bousiou Z; Chatziioannidis A; Batsis I; Mallouri D; Constantinous V; Stavroyianni N; Syrigou A; Marvaki A; Pilavaki M; Papaemmanouel S; Anagnostopoulos A
Hematol Oncol; 2019 Oct; 37(4):490-492. PubMed ID: 31339579
[No Abstract] [Full Text] [Related]
31. Brentuximab vedotin.
Deng C; Pan B; O'Connor OA
Clin Cancer Res; 2013 Jan; 19(1):22-7. PubMed ID: 23155186
[TBL] [Abstract][Full Text] [Related]
32. A malignant lymphoma with histological features and immunophenotypic profile intermediate between EBV-positive diffuse large B-cell lymphoma and EBV-positive classical Hodgkin lymphoma in a 67-year-old female: a "gray zone" lymphoma associated with Epstein-Barr virus in the elderly.
Wang E; Papavassiliou P; Sebastian S
Pathol Res Pract; 2012 Jun; 208(6):363-7. PubMed ID: 22572037
[TBL] [Abstract][Full Text] [Related]
33. A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma.
Oak E; Bartlett NL
Expert Opin Drug Saf; 2016 Jun; 15(6):875-82. PubMed ID: 27139729
[TBL] [Abstract][Full Text] [Related]
34. FDG-PET adapted sequential therapy with brentuximab vedotin and augmented ICE followed by autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma.
Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 6):7. PubMed ID: 24870873
[No Abstract] [Full Text] [Related]
35. Epstein Barr virus-positive mucocutaneous ulcer of the colon associated Hodgkin lymphoma in Crohn's disease.
Moran NR; Webster B; Lee KM; Trotman J; Kwan YL; Napoli J; Leong RW
World J Gastroenterol; 2015 May; 21(19):6072-6. PubMed ID: 26019475
[TBL] [Abstract][Full Text] [Related]
36. Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients.
Zinzani PL; Pellegrini C; Cantonetti M; Re A; Pinto A; Pavone V; Rigacci L; Celli M; Broccoli A; Argnani L; Pulsoni A
Oncologist; 2015 Dec; 20(12):1413-6. PubMed ID: 26500229
[TBL] [Abstract][Full Text] [Related]
37. Brentuximab vedotin desensitization in a patient with refractory Hodgkin's lymphoma.
Arora A; Bhatt VR; Liewer S; Armitage JO; Bociek RG
Eur J Haematol; 2015 Oct; 95(4):361-4. PubMed ID: 25892213
[TBL] [Abstract][Full Text] [Related]
38. Concurrent classical Hodgkin lymphoma and plasmablastic lymphoma in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma treated with fludarabine: a dimorphic presentation of iatrogenic immunodeficiency-associated lymphoproliferative disorder with evidence suggestive of multiclonal transformability of B cells by Epstein-Barr virus.
Foo WC; Huang Q; Sebastian S; Hutchinson CB; Burchette J; Wang E
Hum Pathol; 2010 Dec; 41(12):1802-8. PubMed ID: 20869749
[TBL] [Abstract][Full Text] [Related]
39. Intrathecal rituximab for EBV-associated post-transplant lymphoproliferative disorder with central nervous system involvement unresponsive to intravenous rituximab-based treatments: a prospective study.
Wu M; Sun J; Zhang Y; Huang F; Zhou H; Fan Z; Xuan L; Yu G; Guo X; Dai M; Feng R; Liu Q
Bone Marrow Transplant; 2016 Mar; 51(3):456-8. PubMed ID: 26595071
[No Abstract] [Full Text] [Related]
40. Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Hong JY; Ryu KJ; Park C; Hong M; Ko YH; Kim WS; Kim SJ
Oncotarget; 2017 Feb; 8(8):13782-13791. PubMed ID: 28099151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
